title: Effects of intravenous immunoglobulin in vivo on abnormally increased tumor necrosis factor-alpha activity in human immunodeficiency virus type 1 infection.
abstract: The effect of a single bolus injection (0.4 g/kg) of intravenous immunoglobulin (IVIG) on the tumor necrosis factor (TNF) system in human immunodeficiency virus type 1 (HIV-1)-infected patients was investigated. At 140 h after infusion, there was a significant decrease in levels of TNF-alpha and a significant increase in levels of soluble TNF receptors (sTNFR) in both plasma and lipopolysaccharide-stimulated peripheral blood mononuclear cells (PBMC). A rapid (within 1 h) decline in expression of membrane-bound TNF-alpha and p55-TNFR on PBMC persisted throughout the study. In contrast, there was an increased expression of membrane-bound p75-TNFR after 140 h. IVIG administration also resulted in significantly increased numbers of circulating CD4 lymphocytes, correlated with down-regulation of TNF-alpha activity in PBMC supernatants. Thus, down-regulation of the abnormally increased TNF-alpha activity may be achieved by IVIG administration. Studies evaluating the possible therapeutic role of long-term TNF-alpha suppression by IVIG may be warranted in HIV-1-infected patients.
authors.affiliation: Medical Department A and Research Institute for Internal Medicine, University of Oslo, National Hospital, Rikshospitalet, Norway.
authors.forename: P
authors.initials: P
authors.lastname: Aukrust
authors.forename: K
authors.initials: K
authors.lastname: Hestdal
authors.forename: E
authors.initials: E
authors.lastname: Lien
authors.forename: V
authors.initials: V
authors.lastname: Bjerkeli
authors.forename: I
authors.initials: I
authors.lastname: Nordøy
authors.forename: T
authors.initials: T
authors.lastname: Espevik
authors.forename: F
authors.initials: F
authors.lastname: Müller
authors.forename: S S
authors.initials: SS
authors.lastname: Frøland
mesh_terms: D000328:Adult; D018791:CD4 Lymphocyte Count; D002462:Cell Membrane / Q000378:metabolism; D015536:Down-Regulation; D005260:Female; D005434:Flow Cytometry; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology* / Q000378:metabolism; D015497:HIV-1; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000627:therapeutic use*; D007958:Leukocyte Count; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008070:Lipopolysaccharides / Q000276:immunology; D016131:Lymphocyte Subsets / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000276:immunology; D012367:RNA, Viral / Q000032:analysis; D018124:Receptors, Tumor Necrosis Factor / Q000097:blood / Q000187:drug effects / Q000378:metabolism; D011994:Recombinant Proteins / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism*; D019562:Viral Load
chemical_list: D016756:Immunoglobulins, Intravenous; D008070:Lipopolysaccharides; D012367:RNA, Viral; D018124:Receptors, Tumor Necrosis Factor; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha